Geneva, Switzerland "Highlight of mAb development targeting immunity checkpoints" by Dr Jerome Tiollier, Chief Development Officer, Innate Pharma, France Nov. 28, 2012, 14.20 More info Date mar, 11/27/2012 - 09:00
